Empirical Finance LLC Increases Holdings in Medpace Holdings, Inc. $MEDP

Empirical Finance LLC grew its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 81.0% during the 1st quarter, HoldingsChannel reports. The fund owned 12,663 shares of the company’s stock after purchasing an additional 5,667 shares during the quarter. Empirical Finance LLC’s holdings in Medpace were worth $6,081,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of MEDP. Healthcare of Ontario Pension Plan Trust Fund bought a new position in shares of Medpace during the first quarter valued at $3,041,000. Renaissance Technologies LLC boosted its stake in Medpace by 8.3% in the 1st quarter. Renaissance Technologies LLC now owns 504,668 shares of the company’s stock worth $242,337,000 after purchasing an additional 38,760 shares in the last quarter. Public Employees Retirement System of Ohio boosted its stake in Medpace by 12.1% in the 1st quarter. Public Employees Retirement System of Ohio now owns 17,968 shares of the company’s stock worth $8,628,000 after purchasing an additional 1,941 shares in the last quarter. Compound Planning Inc. grew its position in Medpace by 8.2% during the 1st quarter. Compound Planning Inc. now owns 1,432 shares of the company’s stock valued at $688,000 after purchasing an additional 108 shares during the last quarter. Finally, Keebeck Wealth Management grew its position in Medpace by 9.1% during the 1st quarter. Keebeck Wealth Management now owns 1,434 shares of the company’s stock valued at $689,000 after purchasing an additional 120 shares during the last quarter. 77.98% of the stock is owned by hedge funds and other institutional investors.

More Medpace News

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: Medpace reported stronger-than-expected Q2 results, with EPS of $4.25 topping estimates and revenue of $707.3 million exceeding forecasts, reinforcing momentum in the business. MarketWatch article
• Positive Sentiment: The company raised FY 2026 guidance to EPS of $17.25-$17.95 and revenue of about $2.8 billion-$2.9 billion, signaling confidence in continued growth and backlog conversion. Benzinga article
• Positive Sentiment: Bookings and backlog trends improved, with commentary highlighting a rebound in the net book-to-bill ratio and better revenue visibility, which supports investor optimism about future quarters. Seeking Alpha article
• Neutral Sentiment: Truist raised its price target to $609 from $462 but kept a hold rating, while Robert W. Baird lifted its target to $624 and maintained a neutral stance, suggesting analysts see upside but are not turning fully bullish. Benzinga article
• Neutral Sentiment: The stock’s move to a 52-week high reflects strong recent performance, but one Zacks note questioned whether the rally can continue, indicating the market may now be weighing valuation against the improved fundamentals. Zacks article

Analysts Set New Price Targets

Several research analysts have issued reports on MEDP shares. Leerink Partners set a $620.00 target price on shares of Medpace in a report on Thursday. TD Cowen increased their price target on shares of Medpace from $419.00 to $492.00 and gave the company a “hold” rating in a report on Friday. Wall Street Zen downgraded shares of Medpace from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Barclays set a $600.00 price objective on shares of Medpace in a report on Thursday. Finally, Royal Bank Of Canada upped their price objective on Medpace from $484.00 to $692.00 and gave the company an “outperform” rating in a research report on Friday. Two analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $560.92.

Medpace Stock Performance

Shares of NASDAQ:MEDP opened at $601.38 on Friday. Medpace Holdings, Inc. has a fifty-two week low of $373.00 and a fifty-two week high of $677.90. The business has a 50-day simple moving average of $492.09 and a two-hundred day simple moving average of $494.49. The firm has a market cap of $17.18 billion, a price-to-earnings ratio of 35.25, a price-to-earnings-growth ratio of 2.96 and a beta of 1.15.

Medpace (NASDAQ:MEDP) last posted its earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.98 by $0.27. The business had revenue of $707.33 million for the quarter, compared to analysts’ expectations of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The business’s revenue for the quarter was up 17.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, research analysts predict that Medpace Holdings, Inc. will post 17.45 earnings per share for the current year.

Insiders Place Their Bets

In related news, General Counsel Stephen P. Ewald sold 16,349 shares of the stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the transaction, the general counsel owned 20,343 shares in the company, valued at $9,154,350. This represents a 44.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 20.50% of the stock is currently owned by company insiders.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.